Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.
hepatocellular carcinoma
lenvatinib
regorafenib
sequential therapy
sorafenib
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
06
08
2020
revised:
11
10
2020
accepted:
25
10
2020
pubmed:
17
11
2020
medline:
17
11
2020
entrez:
16
11
2020
Statut:
ppublish
Résumé
Sequential administration of sorafenib followed by regorafenib or lenvatinib is effective against advanced hepatocellular carcinoma (HCC). In this study, we compared the safety profiles and anti-tumor effects of sequential sorafenib and regorafenib or lenvatinib therapy in patients with HCC. We investigated adverse events, treatment responses and dose intensities in patients with HCC who were consecutively treated with sorafenib followed by regorafenib or lenvatinib at the individual level. Each group included 20 patients. The safety profiles of regorafenib and sorafenib were similar. The severity of hypophosphatemia, palmar-plantar erythrodysesthesia syndrome, and decreased neutrophil counts associated with regorafenib or sorafenib was similar in 12 patients. Conversely, the incidences and grades of adverse events differed between sorafenib and lenvatinib treatment. The anti-tumor effects of regorafenib and lenvatinib compared with sorafenib were significantly different for each patient. The response to treatment and progression-free survival were comparable for regorafenib and lenvatinib. The median relative dose intensities during the first 56 days of regorafenib and lenvatinib treatment were 83.6 and 80.0%, respectively. Similar adverse events were experienced by patients during consecutive treatment with sorafenib and regorafenib, which was not observed during treatment with sorafenib and lenvatinib. The obtained safety profile of sorafenib provided meaningful insights for selecting sequential therapy for patients with advanced HCC.
Types de publication
Journal Article
Langues
eng
Pagination
190-200Informations de copyright
© 2020 The Japan Society of Hepatology.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
Yang JD, Mannalithara A, Piscitello AJ et al. Impact of Surveillance for Hepatocellular Carcinoma on Survival in Patients with Compensated Cirrhosis. Hepatology 2018; 68: 78-88.
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017; 153: 996-1005.
Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56-66.
Kissel M, Berndt S, Fiebig L et al. Anti-tumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. Oncotarget 2017; 8: 107096-107108.
Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. Lancet 2018; 391: 1163-1173.
Hiraoka A, Kumada T, Atsukawa M et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. Cancer Med 2019; 8: 3719-3728.
Bruix J, Sheman M. Practice Guidelines Committee, American Association for the study of Liver Diseases. Management ofhepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
Ren Z, Zhu K, Kang H et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-fott skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33: 894-900.
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
Lencioni R, Llovet M et al. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
Finn RS, Merle P, Granito A et al. Outcome of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol 2018; 69: 353-358.
Kuzuya T, Ishigami M, Ito T et al. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatol Res 2019; 49: 1054-1065.
Ogasawara S, Chiba T, Ooka Y et al. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs 2018; 36: 332-339.
Terashima T, Yamashita T, Suangozaka H et al. Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: prospects for regorafenib therapy. Hepatol Res 2018; 48: 956-966.
Uchikawa S, Kawaoka T, Aikata H et al. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 2018; 48: 814-820.
Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 279: 54-63.
Zhu AX, Kang YK, Yen CJ et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20: 282-296.
Yamada K, Yamamoto N, Yamada Y et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 2828-2837.
Kim K, Jha R, Prins PA et al. Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment. Cancer Chemother Pharmacol 2017; 80: 945-954.
Solms A, Reinecke I, Fiala-Buskies S et al. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. Eur J Pharm Sci 2017; 109S: S149-S153.
Kirino S, Tsuchiya K, Kurosaki M et al. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One 2020; 15: e0231828.
Tohyama O, Matsui J, Kodama K et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014; 2014: 638747.
Hiraoka A, Kumada T, Kariyama K et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis. Cancer Med 2019; 8: 137-146.
Hashiba T, Yamashita T, Okada H et al. Inactivation of transcriptional repressor capicua confers chemoresistance to sorafenib in hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol 2020; 10: 269-285.
Sasaki R, Kanda T, Fujisawa M et al. Different mechanisms of action of regorafenib and lenvatinib on toll-like receptor-signaling pathway in human hepatoma cell lines. Int J Med Sci 2020; 21: 3349.
Ogasawara S, Ooka Y, Itokawa N et al. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: A multicenter retrospective study in Japan. Invest New Drugs 2020; 38: 172-180.
Terashima T, Yamashita T, Takata N et al. Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatol Res 2016; 46: 650-656.
Terashima T, Yamashita T, Toyama T et al. Surrogacy of time to progression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: A systematic review and meta-analysis of randomized controlled trial. Liver Cancer 2019; 8: 130-139.